

CONFERENCE OBJECTIVES

To identify potential partners for our pipeline products and identify European investors for our next round of funding.

Also, by participating in the Conference learn the latest trends in the Biopharmaceutical Industry.



ONCONOVA
THERAPEUTICS

RECENT DEVELOPMENTS

The first Phase I clinical trials (at three centers in USA) for lead anticancer compound ON 01910.Na has been completed. Additional Phase I single agent and combination therapy trials are underway.

New compounds, uniquely capable of targeting the T315I mutation of Gleevec™ resistant bcr-abl and JAK2 kinases, have been developed.

The radiation protection drug Ex-RAD™ has been supported by more than \$5 Million in funding from the U.S. Government.

Phase 2 Studies for ON 01910.Na Planned

**ONCONOVA
Therapeutics**
375 Pheasant Run
Newtown, PA 18940
(267) 759-3680
www.onconova.com



James Altland
Senior Vice President

PRODUCT AND PRODUCT CANDIDATE PIPELINE

LEAD PROGRAMS

ON 01910.Na

A potent and selective mitotic inhibitor, with a differential effect on cell cycle progression in tumor cells vs. normal cells. Its primary action on tumor cells is to inhibit the cell cycle progression at the G2-M stages. The Company has begun three Phase I clinical studies in advanced cancer patients, at Johns Hopkins Kimmel Cancer Center in Baltimore, Maryland; Mt. Sinai Hospital in New York; and at Albert Einstein/Montefiore Medical Centers in New York.

ON 01210.Na, or Ex-RAD™

A radiation protection drug candidate for Acute Radiation Syndrome (ARS) in conjunction with the Armed Forces Radiation Research Institute (AFRRI) and the Department of Defense. The radio-protective drug, is a first in class non-steroidal NCE with a novel

mechanism of action and is indicated for prophylactic use to enhance survival in personnel who are in imminent danger of exposure to life-threatening levels of x-ray or gamma radiation. The Company had a pre-IND meeting with FDA in 2006, and is now completing the final steps for filing an IND to start a Phase I clinical study in mid 2008.

ON 013100

Cyclin D1 Accumulation
Pre-IND
IND-H2-2008

Immunoconjugates

Enabling Technology
R&D
Licensing

Bcr-abl/JAK2

Various
Research
IND-2009

Company Description

Onconova is a privately held biopharmaceutical company focused on discovery and development of novel small molecule therapeutics for oncology and cytoprotection. The company's proprietary medicinal chemistry library and cell-based screening platform have yielded many promising drug candidates, including novel bcr-abl directed inhibitors that are active against all known Gleevec®-resistant mutations of this enzyme. This novel anti-leukemic compound is currently in the pre-clinical stage.